Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Biotech
Gilead and Arcus' TIGIT combo continues to show signs of life
Gilead and Arcus are continuing to stake out their claim to the anti-TIGIT market, posting updated phase 2 data at ASCO.
Max Bayer
Jun 3, 2023 1:30pm
Gut microbiota could hold key to why some cancer therapies fail
May 9, 2023 7:20am
Merck exec defends aggressive Keytruda prostate cancer program
Feb 16, 2023 6:30am
Mirati pressures Amgen with Keytruda combo show in lung cancer
Dec 6, 2022 9:15am
ESMO: AstraZeneca's bispecific shows promise but limited by dose
Sep 11, 2022 4:20am
Who might better benefit from KRAS and PD-1 combos?
Jul 26, 2022 3:30am
